FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Novavax

Deals help Novavax pay off $22M in debts

Tools
  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

Flush from a pair of newly inked collaborations, Novavax has paid off the last of its debt.

Novavax began this year--one of the rockiest in biotech history--with $22 million in convertible debt. But the last $5 million was paid off earlier in the week as the developer cleared the books of debt.

Novavax was able to do that by striking a couple of deals. The developer created a new joint venture with India's Cadila to advance Novavax's virus-like particle vaccine for swine flu in the subcontinent. Cadila agreed to invest $11 million in Novavax in order to set up the venture. And just last month Novavax gained a $3 million equity investment from Spain's Rovi after the two companies agreed to collaborate, using Novavax's technology to advance new vaccines.

- check out the story from the Washington Business Journal

Related Articles:
Novavax shares skyrocket on European vax pact
Novavax shares soar on NIH swine flu agreement
Novavax gets $11M, forges Indian joint venture
Novavax cuts staff, seeks partnerships

More stories about Novavax  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.